Parathyroidectomy in secondary (renal) hyperparathyroidism -whom, when, how?
Parathyroid hyperplasia is a homeostatically useful adaptive response to renal failure. Nevertheless, Stanbury et al. (1) were able to document the paradoxical efficacy of parathyroidectomy in reversing hypercalcemic, hyperparathyroidism and osteitis fibrosa in advanced renal failure. Currently, there is much uncertainty about the roles of pharmacological (2) vs. surgical parathyroidectomy and also about the type of surgical intervention, i.e, total vs. subtotal parathyroidectomy (3) . This editorial will briefly address some of the currently controversial issues in this field.
When and why does parathyroid hyperplasia occur?
When the parathyroid gland is exposed to stimulatory signals and confronted with an increased demand for PTH secretion, it will acutely respond: a) By increased secretion of presynthesized hormone through exocytosis and other pathways b) Subsequently by increased hormone synthesis per cell, l.e, increased messenger RNA of pre-pro-PTH per unit weight of DNA (4) and finally c) By proliferation of parathyroid cells (5) . Recruitment of hormonally active cells is thus a very early response. This raises the issue of what controls parathyroid cell proliferation under normal circumstances. Parathyroid cells possess vitamin 0 receptors (6), and 1,25 (OHh 0 3 exerts negative feedback control on the parathyroid cell, both by inhibiting messenger RNA synthesis (4) and by cellular proliferation (5) . In renal patients with severe hyperparathyroidism we found marked regional heterogeneity of nuclear receptor expression, as assessed by immunohistochemistry using monoclonal antibodies (unpublished observation), suggesting that some groups or clones of cells may escape from the negative feedback control via 1, 25 (OHh 0 3 , This is possibly one explanation for the propensity of the parathyroids to undergo nodular hyperplasia in uremia. As shown by Mendez et al. (7) , the size of the parathyroids increases with time on dialysis and a transition occurs from diffuse to nodular hyperplasia. This is reminiscent of the transition from diffuse to nodular hyperplasia and eventually to tumor in other endocrine glands such as in familial hyperaldosteronism type II (8) . Such tumor formation after prolonged stimulation was also suggested by the perhaps higher than chance prevalence of adrenal adenoma ("tertiary hyperaldosteronism") in patients with renal artery stenosis (9) . It would be simplistic, however, to assume that in the parathyroid gland 1,25 (OHh 0 3 is the only regulatory signal. Thus recent studies point to a role for endothelian in the control of parathyroid proliferation (10) . Interesting, endothelin serum concentrations are elevated in renal failure (and possibly -more important -also local tissue concentrations) (11) .
As with endocrine organs in general, reversal of hyperplasia is a very slow process (12) . It occurs not through necrosis but through programmed cell death involving calcium-dependent activation of cellular nucleases, l.e. apoptosis, a process which has been well investigated in immune cells. Such involution of hyperplastic parathyroid glands may take years. Even 10 years after successfu I renal transplantation the weight of parathyroid glands remains elevated (12) . Thus although it has been claimed that parathyroid size by ultrasonography is rapidly reversed after injection of high doses of 1,25 (OHh 0 3 (13), we and others (14) have been unable to confirm this.
Given the limited reversibility of parathyroid hyperplasia, much is to be said for prevention. Although some Authors disagree (15) we feel it is logical to prevent such hyperplasia by timely administration of the lacking endocrine product, i.e, 1,25 (OHh 0 3 , to patients with renal failure. There is no question that 1,25 (OHh 0 3 may cause hypercalciuria, hypercalcemia, hyperphosphatemia and even nephrocalci-nosis (16) . We feel, however, that these complications can be avoided by careful monitoring. Moreover, current prophylactic dosages of 1,25 (OHhD 3 seem to be unnecessarily high. Recent work from our laboratory (17) shows marked and prolonged suppression of mRNA for pre-pro-PTH in the rat after doses of 1,25 (OHh D 3 that come close to the estimated daily rate of secretion of 1,25 (OHh D 3 by the kidney. We care currently carrying out a prospective controlled trial on the efficacy of 0,125 Jig per day of 1,25 (OHh D 3 in preventing renal hyperparathyroidism.
When should prophylactic administration of 1,25 (OH)2 0 3 be considered?
We feel that it is useful to monitor the need of the organism for 1,25 (OHh D 3 by measuring 1,84 iPTH levels. An increase of 1,84 iPTH indicates that the parathyroid has escaped from negative feedback control via 1,25 (OHh D 3 . Consequently it would appear rational to administer 1,25 (OHh D 3 .
If the presence of florid hyperparathyroidism is indicated by a) markedly elevated 1,84 iPTH levels; b) evidence of osteitis fibrosa by X-ray; c) elevated bone isoenzyme of alkaline phosphatase; d) high osteocalcin levels etc. -what are the therapeutic options?
In principle, both "pharmacological parathyroidectomy" by administration of 1,25 (OHh D 3 and surgical parathyroidectomy are reasonable approaches. When considering "pharmacological parathyroidectomy" several important questions have to be answered, e.g. what dose of 1,25 (OHh D 3 should be administered and by what route. Initial reports that intravenous high dose 1,25 (OHh D 3 is efficaceous (2) have been confirmed by other investigators, but later on Japanese Authors (13, 18) and we (19) documented that 1,25 (OHh D 3 in intermittent high doses is also effective when given by mouth. A recent head-on comparison (14) of i.v. vs. p.o. 1,25 (OHh D 3 showed no difference with respect to lowering of 1,84 iPTH levels and a similar incidence of side effects, particularly hypercalcemia, was noted.
While both i.v, and p.o. boli are efficaceous, the optimal timing of the boll has not been well worked out. Recent studies in our laboratory showed that in renal patients the plasma 1,84 iPTH levels decreased 8 consistently and failed to return to baseline levels for more than 96 h after 2 Jig 1,25 (OHh D 3 p.o. (20) . This is reminiscent of experimental studies in which a prolonged decrease of mRNA for pre-pro-PTH was documented after bolus injection of 1,25 (OHh D 3 (14, 21) . It may well be that once weekly administration of 1,25 (OHh D 3 could be sufficient (22) . It is important to strictly control hyperphosphatemia when bolus 1,25 (OHh D 3 therapy is considered. Hyperphosphatemia is favoured by the stimulatory effect of 1,25 (OHh D 3 on active intestinal phosphate absorption. Despite administration of the suppressive agent 1,25 (OHh D 3 the levels of PTH increase in uremic animals when the rise in serum P levels is not prevented (23) .
When should one consider "pharmacological parathyroidectomy" and when surgical reduction of parathyroid mass?
Marked parathyroid hyperplasia will not reverse readily, even after high doses of 1,25 (OHh D 3 , as shown by the study of Fischer (13) and our own observations. Consequently it is logical to consider surgical reduction of parathyroid mass once the estimated size of the parathyroid by ultrasonography exceeds about 1 g. This view is also shared by others (24) . Recent studies using molecular biology techniques provide one further argument. In severely hyperplastic parathyroid glands of uremic patients, monoclonal growth with allelic loss of several genes on chromosome 11 q 13 was found (25) . Interestingly, on this chromosome one PTH gene is coded. The gene for multiple endocrine neoplasia (MEN) has also been located on this chromosome. The deletions on chromosome 11 are thought to eliminate suppressor genes controlling cell growth. In line with these findings, parathyroid autotransplants in renal patients have repeatedly been shown to undergo locally invasive growth (26, 27) even when 1,25 (OHh D 3 is administered, although metastases are exceedingly rare. These findings suggest that the parathyroid cells have escaped from some inhibitory mechanism(s) controlling cell growth.
It has recently been argued that one should prefer total parathyroidectomy (28, 29) over subtotal parathyroidectomy. This advice was based on the consideration that residual parathyroid tissue in the thymus hypertrophies and maintains some residual PTH activity in the circulation. We feel that this advice is mistaken. PTH does indeed have an important longterm role in skeletal homeostasis, i.e, by maintainig a level of remodelling which permits the skeleton a} to adapt its structure to changing biomechanical loads and b) to repair cumulative microdamage. These adaptive responses will be abolished when effective PTH concentrations are abrogated by total parathyroidectomy. It has recently been recognized that reduction of PTH levels to the low normal range may cause low turnover bone disease (30) . In addition, patients with total parathyroidectomy will be dependent upon continuous substitution of 1,25 (OHh D 3 after transplantation.
Should one perform parathyroid autotransplantation or not?
We feel that the two procedures are equivalent. It should be left to the local surgeon whether he prefers subtotal parathyroidectomy (leaving some residual tissue in situ and marking it with a silverclip to facilitate reexploration in case of a relapse) or total parathyroidectomy with parathyroid autotransplantation into the forearm. One recent follow-up of the Necker Hospital (31) gave comparable longterm results for the two techniques.
It goes without saying that the success of parathyroidectomy will depend on whether the indication was correct in the first place. We feel (16) that before parathyroidectomy is considered, a bone biopsy should be done to exclude aluminium intoxication (which, if left untreated, would expose the patient to the risk of osteomalacia father parathyroidectomy) and to exclude the presence of alternative bone pathologies.
CONCLUSION
The problem of parathyroid hyperplasia is another illustration that an ounce of prevention is better than a pound of cure. If prophylactic measures have failed and overt hyperparathyroidism is present, pharmacological intervention with 1,25 (OHh D 3 may be tried. Surgical reduction of parathyroid mass should be considered, however, if gross hyperplasia is present. Recent insights into parathyroid cell and molecular biology provide a clearer rationale for therapeutic approaches than had been at our disposal in the past.
